[{"id":"5e2744aa-d058-4f2c-9e4b-018ea0717e10","acronym":"CR108998","url":"https://clinicaltrials.gov/study/NCT04811560","created_at":"2021-03-23T11:52:16.121Z","updated_at":"2025-02-25T17:00:59.336Z","phase":"Phase 1/2","brief_title":"A Phase 1/2 Study of Bleximenib in Participants With Acute Leukemia","source_id_and_acronym":"NCT04811560 - CR108998","lead_sponsor":"Janssen Research \u0026 Development, LLC","biomarkers":" NPM1 • KMT2A","pipe":"","alterations":" ","tags":["NPM1 • KMT2A"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e bleximenib (JNJ-6617)"],"overall_status":"Recruiting","enrollment":" Enrollment 400","initiation":"Initiation: 05/19/2021","start_date":" 05/19/2021","primary_txt":" Primary completion: 02/16/2026","primary_completion_date":" 02/16/2026","study_txt":" Completion: 10/31/2027","study_completion_date":" 10/31/2027","last_update_posted":"2025-02-03"},{"id":"6dba0cab-3f80-43f0-8cb0-96232c700c74","acronym":"","url":"https://clinicaltrials.gov/study/NCT05521087","created_at":"2022-08-30T20:55:55.553Z","updated_at":"2025-02-25T17:02:06.364Z","phase":"Phase 1","brief_title":"A Study of JNJ-75276617 in Combination With Conventional Chemotherapy for Pediatric and Young Adult Participants With Relapsed/Refractory Acute Leukemias","source_id_and_acronym":"NCT05521087","lead_sponsor":"Janssen Research \u0026 Development, LLC","biomarkers":" NPM1 • KMT2A • NUP98 • NUP214","pipe":"","alterations":" ","tags":["NPM1 • KMT2A • NUP98 • NUP214"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cytarabine • vincristine • Oncaspar liquid (pegaspargase) • fludarabine IV • bleximenib (JNJ-6617)"],"overall_status":"Withdrawn","enrollment":"","initiation":"Initiation: 12/26/2025","start_date":" 12/26/2025","primary_txt":" Primary completion: 09/11/2026","primary_completion_date":" 09/11/2026","study_txt":" Completion: 01/29/2030","study_completion_date":" 01/29/2030","last_update_posted":"2025-02-03"},{"id":"fb6439e5-b767-47e6-9fe0-4ee26349fda0","acronym":"","url":"https://clinicaltrials.gov/study/NCT05453903","created_at":"2022-07-12T10:54:42.198Z","updated_at":"2024-07-02T16:35:01.650Z","phase":"Phase 1","brief_title":"A Study of JNJ-75276617 in Combination With Acute Myeloid Leukemia (AML) Directed Therapies","source_id_and_acronym":"NCT05453903","lead_sponsor":"Janssen Research \u0026 Development, LLC","biomarkers":" NPM1 • KMT2A","pipe":"","alterations":" ","tags":["NPM1 • KMT2A"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Venclexta (venetoclax) • cytarabine • azacitidine • daunorubicin • idarubicin hydrochloride • bleximenib (JNJ-6617)"],"overall_status":"Recruiting","enrollment":" Enrollment 150","initiation":"Initiation: 10/04/2022","start_date":" 10/04/2022","primary_txt":" Primary completion: 05/15/2024","primary_completion_date":" 05/15/2024","study_txt":" Completion: 03/05/2026","study_completion_date":" 03/05/2026","last_update_posted":"2024-05-23"}]